Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
To show if a combination therapy of rivaroxaban plus Aspirin® is more efficient (superiority
testing) as rivaroxaban alone in the prevention of early venous stent thrombosis in patients
suffering from post-thrombotic syndrome in the first 6 months following endovascular therapy
To demonstrate tolerability of combination therapy of Aspirin® plus rivaroxaban in long-term
treatment.
Phase:
Phase 2
Details
Lead Sponsor:
University of Zurich
Collaborators:
Klinikum Arnsberg Medical University of Vienna RWTH Aachen University University Hospital Heidelberg